Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
Similar News
expand_more
Science
Science
Science
1 w.
Opinion: Canada has the knowledge to prevent kidney disease — now we need to put it into action
Science
Technology
Science
Technology
Technology
Economics
Science